NetworkNewsBreaks – CytoDyn Inc. (CYDY) Interim CMO to Present at 11th Annual Conference on Stem Cell and Regenerative Medicine

CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning announced that Richard G. Pestell, M.D., Ph.D., president of the Pennsylvania Cancer and Regenerative Medicine Research Center, distinguished professor at the Baruch S. Blumberg Institute and interim chief medical officer of CytoDyn, will deliver the keynote plenary speech at the 11th Annual Conference on Stem Cell and Regenerative Medicine in Helsinki, Finland. Pestell’s presentation, titled ‘Cancer stem cells, genetic drivers and therapeutic targeting via CCR5’, is scheduled to take place on Monday, October 15, from 10-11 am EEST. Pestell will present recent scientific evidence demonstrating the effectiveness of PRO 140 (leronlimab), which is shown to bind to CCR5 in human breast cancer, block CCR5 signaling induced by cytokines and block human breast cancer cell invasion.

To view the full press release, visit http://nnw.fm/SgzM0

About CytoDyn

CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com

More from NetworkNewsBreaks

NetworkNewsBreaks – FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Investee Adds Taxation Reporting Technology to its Proprietary Compliance Platform NetworkNewsBreaks – First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Announces Results of Independent Studies Supporting Restart of Canadian Refinery NetworkNewsBreaks – The Flowr Corporation (TSX.V: FLWR) Ships Initial Purchase Order from the NSLC

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.

More News From Asean Coverage

Hanoi summit nightmare scenario: Bad deals and little change

Feb 24, 2019

HANOI, Vietnam — The nightmare scenario heading into the second summit between President Donald Trump and North Korean leader Kim Jong Un isn't so much "fire and fury" and millions dead. Rather, some experts fear the meeting could result in an ill-considered deal that allows North Korea to get everything it wants while giving up very little, even as the mercurial leaders trumpet a blockbuster nuclear success. There's little argument that just sitting down together again in the same room this week in Hanoi is a positive sign for two men who seemed to be flirting with a second Korean...

North Korea leader Kim Jong Un boards train to summit

Feb 24, 2019

DANDONG, China — North Korea leader Kim Jong Un was on a train Sunday to Vietnam for his second summit with President Donald Trump, state media confirmed. Kim was accompanied by Kim Yong Chol, who has been a key negotiator in talks with the U.S., and Kim Yo Jong, the leader's sister, the North's official Korean Central News Agency reported. TV footage and photos distributed by the North's state-run news agency showed Kim inspecting a guard of honor at the Pyongyang station before waving from the train. Late Saturday, an Associated Press reporter saw a green-and-yellow train similar to one...

Japan scholar and translator Donald Keene has died at 96

Feb 24, 2019

TOKYO — Donald Keene, a longtime Columbia University professor who was a giant in the field of Japanese literature and translation, died Sunday in Tokyo, the city that he had made his home. He was 96. His death was confirmed by Akira Someya, secretary general of the Donald Keene Center Kashiwazaki in Japan's Niigata prefecture. Someya said the cause of death was heart failure. A grandfather-like figure to generations of students, Keene fostered the growth of Japanese studies, a field that barely existed when he started as a Columbia undergraduate in the 1940s. The prolific scholar, who worked well into...

Okinawa votes in referendum on US military base relocation

Feb 24, 2019

TOKYO — The people of Okinawa are voting Sunday on a plan for a U.S. military base relocation in a referendum that will send a message on how they feel about housing American troops in Japan, who many see as a burden on the group of tiny southwestern islands. The referendum is technically not binding but interest is high for testing the public sentiment about the plan to relocate Futenma air base, which is pushed by the national government of Prime Minister Shinzo Abe. The plan has its beginnings in 1995, when outrage erupted against U.S. service members over the...

Japan's crown prince hopes to continue father's legacy

Feb 24, 2019

TOKYO — Japanese Crown Prince Naruhito says he hopes to continue the close relationship his father built with the people when he succeeds him as emperor later this year. Naruhito, who turned 59 on Saturday, will ascend the Chrysanthemum Throne on May 1 after Emperor Akihito abdicates. "I feel very solemn when I think about the future," he said at an annual pre-birthday news conference Thursday. His remarks were embargoed from publication until Saturday. "While I continue to prepare for this role, I would like to maintain the past emperors' work. I would like to think about the people and...